Evidence map›Paper›PMID 39190108›Full record

ArticleJournal of neurology2024

Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA).

Clara Grazia Chisari, Maria Pia Amato, Alessia Di Sapio, Matteo Foschi, Pietro Iaffaldano, Matilde Inglese, Salvatore Lo Fermo, Alessandra Lugaresi, Giacomo Lus, Nerina Mascoli and 9 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Linking Pathogenesis to Fall Risk in Multiple Sclerosis.Archives of internal medicine research · 2025
    Article
  6. Article
  7. Patterns and predictors of transition between multiple sclerosis phenotypes: A longitudinal analysis.Multiple sclerosis journal - experimental, translational and clinical
    Article
  8. Assessment of the impact of outcome definitions on power in multiple sclerosis clinical trials.Multiple sclerosis journal - experimental, translational and clinical
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Clara Grazia ChisariDepartment of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", Multiple Sclerosis Center, University of Catania, Catania, Italy.
Maria Pia AmatoDepartment of NEUROFARBA, Section of Neurosciences, University of Florence, Florence, Italy.
Alessia Di SapioDepartment of Neurology, Regional Referral Multiple Sclerosis Center, University Hospital San Luigi Gonzaga, Orbassano, Turin, Italy.
Matteo FoschiDepartment of Neuroscience, Multiple Sclerosis Center, S. Maria delle Croci Hospital of Ravenna, Ravenna, Italy.
Pietro IaffaldanoDepartment of Translational Biomedicine and Neurosciences (DiBraiN), University of Bari Aldo Moro, Bari, Italy.
Matilde IngleseDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.
Salvatore Lo FermoMultiple Sclerosis Unit; Neurology Clinic, Policlinico "G. Rodolico- San Marco", Catania, Italy.
Alessandra LugaresiUOSI Riabilitazione Sclerosi Multipla, IRCCS Istituto Delle Scienze Neurologiche Di Bologna, Bologna, Italy.
Giacomo LusMultiple Sclerosis Center, Second Division of Neurology, Department of Advanced Medical and Surgical Science, University of Campania Luigi Vanvitelli, Naples, Italy.
Nerina MascoliNeurology Unit, Department of Medicine, S. Anna Hospital, Como, Italy.
Sara MontepietraMS Centre, SMN Hospital, AUSL Reggio Emilia, Reggio Emilia, Italy.
Ilaria PesciCentro Sclerosi Multipla Unità Operativa Neurologia, Azienda Unità Sanitaria Locale, Ospedale Di Vaio, Fidenza, Parma, Italy.
Rocco QuatraleDipartimento Di Scienze Neurologiche, UOC Di Neurologia, Ospedale Dell'Angelo AULSS 3 Serenissima, Venice Mestre, Italy.
Giuseppe SalemiDepartment of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy.
Valentina Torri ClericiNeuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Rocco TotaroDemyelinating Disease Center, San Salvatore Hospital, L'Aquila, Italy.
Paola ValentinoInstitute of Neurology, University Magna Graecia, Catanzaro, Italy.
Massimo FilippiNeuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Francesco PattiDepartment of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", Multiple Sclerosis Center, University of Catania, Catania, Italy. patti@unict.it.ORCID http://orcid.org/0000-0002-6923-0846

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

'Active' and 'non-active' secondary progressive MS (SPMS) have distinct pathophysiological mechanisms and clinical characteristics, but there is still no consensus regarding the frequency of these MS forms in the real-world setting. We aimed to evaluate the frequency of 'active' and 'non-active' SPMS in a large cohort of Italian MS patients and the differences in terms of clinical and MRI characteristics and disease progression. This multicenter study collected data about MS patients who have transitioned to the SP form in the period between 1st January 2014 and 31st December 2019 and followed by the MS centers contributing to the Italian MS Registry. Patients were divided into 'active SPMS' and 'non-active SPMS', based on both reported MRI data and relapse activity in the year before conversion to SPMS. Out of 68,621, 8,316 (12.1%) patients were diagnosed with SPMS. Out of them, 872 (10.5%) were classified into patients with either 'active' or 'non-active' SPMS. A total of 237 were classified into patients with 'active SPMS' (27.2%) and 635 as 'non-active SPMS' (72.8%). 'Non-active SPMS' patients were older, with a longer disease duration compared to those with 'active SPMS'. The percentages of patients showing progression independent of relapse activity (PIRA) at 24 months were similar between 'active' and 'non-active' SPMS patients (67 [27.4%] vs 188 [29.6%]; p = 0.60). In the 'active' group, 36 (15.2%) patients showed relapse-associated worsening (RAW). Comparison of the survival curves to EDSS 6 and 7 according to disease activity did not show significant differences (p = 0.68 and p = 0.71). 'Active' and 'non-active' SPMS patients had a similar risk of achieving disability milestones, suggesting that progression is primarily attributed to PIRA and only to a small extent to disease activity.

Indexed as

Disease ProgressionMultiple Sclerosis, Chronic ProgressiveRegistriesAdultDisability EvaluationFemaleHumansItalyMagnetic Resonance ImagingMaleMiddle AgedDisease activityProgressionSecondary progressive multiple sclerosis

Identifiers

PMID39190108
PMCPMC11446943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.